Antibody discovery technology plays a vital role in drug development, mainly discovering antibodies with specific binding activity by screening antibody libraries or antibodies obtained from animal immunization. This can help researchers accelerate the drug development process. It can also help researchers better understand diseases, including disease pathogenesis and discovering new therapeutic targets.
Services
Medicilon's hybridoma R&D services can provide a variety of immunization methods (proteins, peptides, small molecules, whole cells) to meet with the client's needs.
Medicilon now offers camelid VHH antibody library construction services, including antigen preparation, immunization, construction of antibody library bacteria, nanobody selection, ELISA verification and other related experiments.
Medicilon can provide Single B Cell antibody discovery service, which contains Single B Cell Sorting, Single B cell Ig Gene Transcription, Amplification, and Sequencing.
Medicilon has rich experience in ADA development and has successfully delivered more than 100 projects. Medicilon can provide high-affinity and specific polyclonal anti-drug antibody development services with short development cycles and low costs.
Medicilon provides in vitro study of antibody, including: ADCC, CDC, ADCP, Binding/blocking experiments, Antibody endocytosis, T cell activation, T cell cytotoxicity, etc.
Medicilon can provide ADA rabbit polyclonal antibody development, ADA mouse hybridoma monoclonal antibody development, phage display rabbit monoclonal antibody development services, mouse monoclonal antibody development technical services, and mouse/rabbit single B cell antibody development technical services, etc.
Relevant articles
marketing@medicilon.com
